KLEA HOLDING Stock: price and directors' dealings · France · AMFSource id RS00005261 ISIN ISIN FR0013481835FR · AMF Mcap €49M 医疗与制药 Follow the KLEA HOLDING share price and the full management transaction log of the company, a listed issuer based in France. Shares are quoted on the FR market, under the oversight of AMF. Operating in the Healthcare & Pharma sector, KLEA HOLDING has recorded 78 insider filings. Market capitalisation: €49m. The latest transaction was filed on 20 July 2026 (Acquisition). Among the most active insiders: RAPHAEL SMILA. The full history is free.
Fundamental score
Ranked 6,448 of 28,932 companies
FCF yld 8.3%
Earn yld 4.9%
EV/EBITDA 9.8x
ROE 8.2%
Gross mgn 44%
Net mgn 10%
Debt/EBITDA 1.0x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 July 2026
All Executives78 Thresholds0 Prospectus0 Other0
Declarations 78 total
▲ PDG · Executives · 16 Jul 2026
87,000 shares @ €0.177 0.028% mcap 1.9% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1127565 Canonical exit: 14 Oct 2026 (T+90) ▲ PDG · Executives · 17 Jul 2026
103,000 shares @ €0.174 0.033% mcap 2.2% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1127566 Canonical exit: 15 Oct 2026 (T+90) ▲ PDG · Executives · 9 Mar 2026
95,000 shares @ €0.1898 0.031% mcap 2.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1099718 Canonical exit: 7 Jun 2026 (T+90) ▲ PDG · Executives · 9 Mar 2026
167,212 shares @ €0.1907 0.055% mcap 4.0% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1099711 Canonical exit: 7 Jun 2026 (T+90) ▲ PDG · Executives · 6 Mar 2026
40,000 shares @ €0.202 0.014% mcap 1.0% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1099640 Canonical exit: 4 Jun 2026 (T+90) ▲ PDG · Executives · 6 Mar 2026
25,000 shares @ €0.204 0.0087% mcap 0.6% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1099644 Canonical exit: 4 Jun 2026 (T+90) ▲ pdg · Executives · 4 Mar 2026
80,000 shares @ €0.1909 0.026% mcap 45.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1098784 Canonical exit: 2 Jun 2026 (T+90) ▲ PDG · Executives · 3 Mar 2026
310,000 shares @ €0.1884 0.10% mcap 7.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1098400 Canonical exit: 1 Jun 2026 (T+90) ▲ PDG · Executives · 3 Mar 2026
400,000 shares @ €0.1893 0.13% mcap 9.5% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1098401 Canonical exit: 1 Jun 2026 (T+90) ▲ PDG · Executives · 2 Mar 2026
301,243 shares @ €0.1963 0.10% mcap 7.4% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1098004 Canonical exit: 31 May 2026 (T+90) ▲ PDG · Executives · 2 Mar 2026
320,000 shares @ €0.1948 0.11% mcap 7.8% of flow Action Euronext Growth ParisISIN ISIN FR00134818352026DD1098038 Canonical exit: 31 May 2026 (T+90) ▲ PDG · Executives · 23 Dec 2025
53,156 shares @ €0.2298 1.5% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1086246 Canonical exit: 23 Mar 2026 (T+90) ▲ PDG · Executives · 23 Dec 2025
79,613 shares @ €0.2275 2.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1086247 Canonical exit: 23 Mar 2026 (T+90) ▲ PDG · Executives · 25 Nov 2025
40,000 shares @ €0.2465 1.2% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1071404 Canonical exit: 23 Feb 2026 (T+90) ▲ PDG · Executives · 4 Nov 2025
65,000 shares @ €0.2344 1.9% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1067512 Canonical exit: 2 Feb 2026 (T+90) ▲ PDG · Executives · 4 Nov 2025
5,000 shares @ €0.246 0.2% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1067513 Canonical exit: 2 Feb 2026 (T+90) ▲ pdg · Executives · 3 Nov 2025
40,000 shares @ €0.2428 28.8% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1067131 Canonical exit: 1 Feb 2026 (T+90) ▲ pdg · Executives · 28 Oct 2025
16,720 shares @ €0.257 12.8% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1067128 Canonical exit: 26 Jan 2026 (T+90) ▲ PDG · Executives · 20 Oct 2025
20,000 shares @ €0.2525 0.6% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1064485 Canonical exit: 18 Jan 2026 (T+90) ▲ PDG · Executives · 20 Oct 2025
40,000 shares @ €0.2535 1.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1064486 Canonical exit: 18 Jan 2026 (T+90) ▲ PDG · Executives · 16 Oct 2025
70,000 shares @ €0.2538 2.2% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1064483 Canonical exit: 14 Jan 2026 (T+90) ▲ PDG · Executives · 2 Sept 2025
50,000 shares @ €0.2045 1.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1055928 Canonical exit: 1 Dec 2025 (T+90) ▲ PDG · Executives · 2 Sept 2025
15,000 shares @ €0.213 0.4% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1055940 Canonical exit: 1 Dec 2025 (T+90) ▲ PDG · Executives · 2 Sept 2025
50,000 shares @ €0.212 1.3% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1055941 Canonical exit: 1 Dec 2025 (T+90) ▲ PDG · Executives · 21 Aug 2025
15,000 shares @ €0.205 0.4% of flow Action Euronext Growth ParisISIN ISIN FR00134818352025DD1054448 Canonical exit: 19 Nov 2025 (T+90) 25 of 78 declarations
Load more (53 remaining) 关于 KLEA HOLDING Klea Holding 是一家法国上市公司,在巴黎泛欧交易所增长市场交易,ISIN 代码为 FR0013481835,股票代码为 ALKLH。该公司处于医疗保健、数字服务和投资控股活动的交汇点。其起源可追溯到 2007 年,当时它作为医疗设备领域的创新者起步。随着时间的推移,该公司已转型为一家国际投资和运营控股公司,专注于收购、开发和数字化多个行业的业务,以实现增长和价值最大化。
Klea Holding 当前的战略围绕着严谨的资本配置框架、相对较低的负债资产负债表以及经验丰富的治理结构。该集团将自己定位为一家永久性投资和运营控股公司,拥有提供稳定性和连续性的参考股东。管理层强调敏捷性、透明度以及对子公司的支持,目标是改善融资渠道,同时保持财务灵活性。实际上,这意味着 Klea Holding 既是投资者,也是其运营公司的积极合作伙伴。
在运营方面,该集团的投资组合突出了对医疗保健和数字服务的明确关注。其子公司和投资包括 Smart Salem、Smart Health 和 Bewellthy。Smart Salem 与数字化医疗诊断中心相关联,而 Smart Health 和 Bewellthy 则定位于创新医疗解决方案、互联健康和远程会诊。这些资产表明该公司重视技术驱动的医疗保健服务,其中数字化、流程效率和患者便利性是核心竞争因素。
在地理上,Klea Holding 已建立了国际足迹,业务遍及阿拉伯联合酋长国、沙特阿拉伯、法国和更广泛的欧盟。这一布局使该集团能够接触到对数字医疗保健、医疗筛查和远程医疗解决方案需求持续增长的市场。最近的公司通讯显示出强劲的势头,包括报告称 2025 年按固定汇率计算的盈利收入增长了 34%,这突显了该公司的运营执行力。另一个值得注意的发展是 2026 年宣布成立 Klea Pharmaceuticals,这表明医疗保健领域将进一步多元化。